Examples of MAOI Medications
MAOIs are categorized into irreversible and reversible inhibitors, with specific examples including phenelzine, tranylcypromine, moclobemide, selegiline transdermal, and isocarboxazid.
Classification and Specific Agents
Third-Line Irreversible MAO Inhibitors
These irreversible MAOIs carry the highest side effect burden with potential serious drug and dietary interactions, placing them as third-line antidepressants 1.
Second-Line MAO Inhibitors
- Moclobemide: 300-600 mg daily - a reversible inhibitor of MAO-A 1
- Selegiline transdermal: 6-12 mg daily transdermal - an irreversible MAO-B inhibitor 1
These agents have a higher side effect burden than first-line antidepressants but are considered safer than the traditional irreversible MAOIs 1.
Additional MAOIs
- Isocarboxazid 2
- Isoniazid (also used as an antibiotic) 2
- Linezolid (antibiotic with MAOI properties) 2
Critical Safety Considerations
All MAOIs are contraindicated in combination with other serotonergic drugs due to severe risk of serotonin syndrome 2. This includes combinations with:
- SSRIs, SNRIs, TCAs
- Opioids (tramadol, meperidine, methadone, fentanyl)
- Dextromethorphan
- Amphetamines
- MDMA and other illicit stimulants
Traditional irreversible MAOIs (phenelzine, tranylcypromine, isocarboxazid) require strict dietary tyramine restrictions to prevent hypertensive crisis 2. Foods to avoid include aged cheeses, aged meats, and certain alcoholic beverages.
Moclobemide, as a reversible MAO-A inhibitor, has significantly reduced risk of tyramine-induced hypertensive crisis compared to irreversible MAOIs 3, making it one of the most well-tolerated options in this class.
Clinical Context
MAOIs are reserved for treatment-resistant depression due to their interaction profile 4. Recent network meta-analysis demonstrates that isocarboxazid, phenelzine, tranylcypromine, and moclobemide show significantly higher efficacy compared with placebo, with tolerability comparable to other antidepressants 4. However, the combination risks necessitate their positioning as second- or third-line agents 1, 5.